Patents by Inventor Mark Gelfand

Mark Gelfand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160192985
    Abstract: Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Application
    Filed: March 14, 2016
    Publication date: July 7, 2016
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Publication number: 20160184012
    Abstract: Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, monopolar neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such monopolar neuromodulation is performed bilaterally.
    Type: Application
    Filed: March 14, 2016
    Publication date: June 30, 2016
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Howard R. Levin, Mark Gelfand, Nicolas Zadno
  • Patent number: 9370661
    Abstract: A method and apparatus for treatment of hypertension and heart failure by increasing secretion of endogenous atrial hormones by pacing of the heart atria. Atrial pacing is done during the ventricular refractory period resulting in premature atrial contraction that does not result in ventricular contraction. Pacing results in the atrial wall stress, peripheral vasodilation, ANP secretion. Concomitant reduction of the heart rate is monitored and controlled as needed with backup pacing.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: June 21, 2016
    Assignee: BackBeat Medical, Inc.
    Inventors: Howard Levin, Mark Gelfand
  • Patent number: 9327122
    Abstract: Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, monopolar neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such monopolar neuromodulation is performed bilaterally.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: May 3, 2016
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Howard R. Levin, Mark Gelfand, Nicolas Zadno
  • Patent number: 9320561
    Abstract: Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: April 26, 2016
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Patent number: 9314630
    Abstract: A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve. Therapy is accomplished by at least partially blocking the nerve with drug infusion or electrostimulation. Apparatus can be permanently implanted or catheter based.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: April 19, 2016
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Howard R. Levin, Mark Gelfand
  • Publication number: 20160100883
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for extravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Application
    Filed: October 8, 2015
    Publication date: April 14, 2016
    Inventors: Mark Deem, Denise Zarins, Douglas Sutton, Hanson Gifford, III, Howard R. Levin, Mark Gelfand, Benjamin J. Clark
  • Patent number: 9308044
    Abstract: Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: April 12, 2016
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Patent number: 9308043
    Abstract: Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, monopolar neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such monopolar neuromodulation is performed bilaterally.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: April 12, 2016
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Howard R. Levin, Mark Gelfand, Nicolas Zadno
  • Publication number: 20160095862
    Abstract: Drug eluting implants for targeted delivery of a nerve-blocking agent to inhibit neural traffic along renal nerves of a human patient.
    Type: Application
    Filed: October 8, 2015
    Publication date: April 7, 2016
    Inventors: Mark Gelfand, Howard R. Levin
  • Patent number: 9295846
    Abstract: A lead system for an implantable medical device and applications for the lead system. Also includes therapeutic systems, devices, and processes for detecting and treating disordered breathing and treating cardiac and breathing issues together with an implantable device.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: March 29, 2016
    Assignee: Respicardia, Inc.
    Inventors: Randy W. Westlund, Kristofer J. James, Mark Gelfand
  • Patent number: 9289255
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: March 22, 2016
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Mark E. Deem, Hanson Gifford, III, Denise Zarins, Douglas Sutton, Erik Thai, Mark Gelfand, Howard R. Levin
  • Patent number: 9283033
    Abstract: Methods and devices for assessing, and treating patients having sympathetically mediated disease, involving augmented peripheral chemoreflex and heightened sympathetic tone by reducing chemosensor input to the nervous system via carotid body ablation.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: March 15, 2016
    Assignee: CIBIEM, INC.
    Inventors: Mark Gelfand, Charles Lennox, Ary Chernomorsky, Howard Levin, Veijo T. Suorsa, Kenneth M. Martin, Yegor D. Sinelnikov
  • Patent number: 9265558
    Abstract: Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: February 23, 2016
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Publication number: 20160038212
    Abstract: Catheter apparatuses, systems, and methods for cryogenically modulating neural structures of the renal plexus by intravascular access are disclosed herein. One aspect of the present application, for example, is directed to apparatuses, systems, and methods that incorporate a catheter treatment device comprising an elongated shaft. The elongated shaft is sized and configured to deliver a cryo-applicator to a renal artery via an intravascular path. Cryogenic renal neuromodulation may be achieved via application of cryogenic temperatures to modulate neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers.
    Type: Application
    Filed: July 15, 2015
    Publication date: February 11, 2016
    Applicant: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Eric Ryba, Naomi Buckley, Benjamin J. Clark, Danny Donovan, Luke Hughes, Brian Kelly, Gwenda McMullin, Karun D. Naga, Stephen Nash, Roman Turovskiy, Lana Wooley, Denise Zarins, Mark Gelfand, Mark S. Leung
  • Publication number: 20160030736
    Abstract: Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Application
    Filed: August 3, 2015
    Publication date: February 4, 2016
    Inventors: Denise Zarins, Hanson Gifford, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Publication number: 20160023022
    Abstract: Methods and apparatus are provided for thermally-induced renal neuromodulation. Thermally-induced renal neuromodulation may be achieved via direct and/or via indirect application of thermal energy to heat or cool neural fibers that contribute to renal function, or of vascular structures that feed or perfuse the neural fibers. In some embodiments, parameters of the neural fibers, of non-target tissue, or of the thermal energy delivery element, may be monitored via one or more sensors for controlling the thermally-induced neuromodulation. In some embodiments, protective elements may be provided to reduce a degree of thermal damage induced in the non-target tissues.
    Type: Application
    Filed: October 5, 2015
    Publication date: January 28, 2016
    Inventors: Denise Zarins, Nicolas Zadno, Benjamin J. Clark, Erik Thai, Howard R. Levin, Mark Gelfand
  • Publication number: 20160000499
    Abstract: Methods and endovascular catheters for assessing, and treating patients having sympathetically mediated disease, involving augmented peripheral chemoreflex and heightened sympathetic tone by reducing chemosensor input to the nervous system via transmural carotid body modulation using a catheter with an ionic liquid stream electrode.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 7, 2016
    Inventors: Charles LENNOX, Vahid SAADAT, Mark GELFAND
  • Publication number: 20160001072
    Abstract: An implantable medical device for treating breathing disorders such as central sleep apnea wherein stimulation is provided to the phrenic never through a transvenous lead system with the stimulation beginning after inspiration to extend the duration of a breath and to hold the diaphragm in a contracted condition.
    Type: Application
    Filed: May 18, 2015
    Publication date: January 7, 2016
    Inventors: Mark Gelfand, Howard R. Levin, Andrew Halpert
  • Publication number: 20150374996
    Abstract: A method and apparatus for treatment of heart failure, hypertension and renal failure by stimulating the renal nerve. The goal of therapy is to reduce sympathetic activity of the renal nerve. Therapy is accomplished by at least partially blocking the nerve with drug infusion or electrostimulation. Apparatus can be permanently implanted or catheter based.
    Type: Application
    Filed: September 4, 2015
    Publication date: December 31, 2015
    Inventors: Howard R. Levin, Mark Gelfand